Clinical improvement after change of therapy from tafamidis to patisiran in progressive TTR amyloidosis post-liver transplantation

J Neurol. 2022 Jul;269(7):3912-3914. doi: 10.1007/s00415-022-10978-3. Epub 2022 Feb 6.

Authors

Catherine Bulinski¹, Thomas Discher², Wiebke Rutsatz³, Birgit Assmus³, Heidrun H Krämer⁴

Affiliations

¹ Department of Internal Medicine, Infeciology, Justus Liebig University, Klinikstrasse 33, 35392, Giessen, Germany. catherine.bulinski@innere.med.uni-giessen.de.
² Department of Internal Medicine, Infeciology, Justus Liebig University, Klinikstrasse 33, 35392, Giessen, Germany.
³ Department of Cardiology, Justus Liebig University, Giessen, Germany.
⁴ Department of Neurology, Justus Liebig University, Giessen, Germany.

No abstract available

Publication types

Letter

MeSH terms

Amyloid Neuropathies, Familial* / complications
Amyloid Neuropathies, Familial* / drug therapy
Benzoxazoles / therapeutic use
Humans
Liver Transplantation*
Prealbumin
RNA, Small Interfering / therapeutic use

Substances

Benzoxazoles
Prealbumin
RNA, Small Interfering
patisiran
tafamidis